Deal Tracker · Countries

South Korea pharma licensing deals

6 licensing deals involving South Korea tracked by EPT (2025–2026). Most active: Arcera Life Sciences, AriBio, Autotelic Bio & Bukwang Pharmaceutical. Latest: Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).

6
deals tracked
4
announced in 2026
$696.7m
disclosed value (3 deals)
100%
licensing, the top deal type
  • EPT has tracked 6 South Korea pharma licensing deals (2025–2026), 4 of them announced in 2026.
  • The countries that appear most often are Saudi Arabia (2), UAE (2), Bahrain (1) & Egypt (1).
  • Values were disclosed for 3 of 6 deals, totalling $696.7m; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
  • The most active companies: Arcera Life Sciences (2).

Most active companies

Arcera Life Sciences (2)

Countries involved

Saudi Arabia (2) · UAE (2) · Bahrain (1) · Egypt (1) · Iraq (1) · Italy (1)

Largest disclosed deals

Questions

How many South Korea pharma licensing deals has EPT tracked?
6 as of 4 Nov 2026, covering 2025–2026; 4 were announced in 2026. The most recent is Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).
Which companies are most active in South Korea pharma licensing deals?
Arcera Life Sciences (2 deals).
What is the largest disclosed South Korea pharma licensing deal?
AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Bukwang Pharmaceutical → NASAQ: $2.7m (Licensing, 4 Nov 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)